Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EVGN 
Evogene (EVGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: EVGN (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.5
1 Year Target Price $3.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.53% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.63M USD | Price to earnings Ratio - | 1Y Target Price 3.5 |
Price to earnings Ratio - | 1Y Target Price 3.5 | ||
Volume (30-day avg) 2 | Beta 1.36 | 52 Weeks Range 0.95 - 6.80 | Updated Date 06/30/2025 |
52 Weeks Range 0.95 - 6.80 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -224.82% | Operating Margin (TTM) -168.82% |
Management Effectiveness
Return on Assets (TTM) -35.1% | Return on Equity (TTM) -91.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14792311 | Price to Sales(TTM) 1.72 |
Enterprise Value 14792311 | Price to Sales(TTM) 1.72 | ||
Enterprise Value to Revenue 2.19 | Enterprise Value to EBITDA -0.81 | Shares Outstanding 8714230 | Shares Floating 6606385 |
Shares Outstanding 8714230 | Shares Floating 6606385 | ||
Percent Insiders 1.26 | Percent Institutions 6.46 |
Analyst Ratings
Rating 2 | Target Price 3.5 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Evogene
Company Overview
History and Background
Evogene Ltd. was founded in 1999. It focuses on utilizing computational biology to develop novel products for life science markets, primarily agriculture, and recently expanded into human health.
Core Business Areas
- Ag Seed Traits: Focuses on improving crop yields, stress tolerance, and disease resistance through genetic modification and breeding.
- Biologicals: Develops microbial-based products for crop protection and enhancement, aiming for sustainable agricultural practices.
- Human Health: Evogene entered human health through its subsidiary, Biomica, focusing on microbiome-based therapeutics.
Leadership and Structure
Evogene's leadership team consists of experienced professionals in biotechnology, agriculture, and business management. The company has a hierarchical organizational structure with distinct divisions for each business area.
Top Products and Market Share
Key Offerings
- Ag Seed Traits: Improved seed varieties with enhanced yields and resistance to pests and diseases. Specific market share data is difficult to isolate for Evogene. Competitors include Bayer (BAYRY), Corteva (CTVA), and Syngenta (SNYNY).
- Biologicals: Microbial-based products for biocontrol, biofertilization, and biostimulation. Market share is fragmented; competitors include Bayer (BAYRY), Corteva (CTVA), and Novozymes (NVZMY).
- Microbiome-based therapeutics: Therapies developed to treat different illnesses by manipulating the microbiome
Market Dynamics
Industry Overview
The agricultural biotechnology and microbiome therapeutic industries are experiencing significant growth, driven by increasing demand for sustainable agriculture and personalized medicine.
Positioning
Evogene is positioned as an innovation-driven company utilizing computational biology to create novel solutions for agriculture and human health. Its competitive advantage lies in its computational biology platform.
Total Addressable Market (TAM)
The TAM for agricultural biotechnology is estimated to be hundreds of billions of USD annually, with microbiome therapeutics reaching billions of USD. Evogene is targeting specific segments within these markets, leveraging its technology platform.
Upturn SWOT Analysis
Strengths
- Proprietary computational biology platform
- Strong R&D capabilities
- Experienced management team
- Diverse product pipeline
Weaknesses
- Relatively small size compared to major players
- Limited commercialized products
- Dependence on partnerships
- High R&D expenses
Opportunities
- Growing demand for sustainable agriculture
- Expanding microbiome therapeutics market
- Potential for strategic partnerships
- Increased adoption of precision agriculture
Threats
- Regulatory hurdles
- Competition from larger companies
- Technological advancements by competitors
- Fluctuations in agricultural commodity prices
Competitors and Market Share
Key Competitors
- Bayer (BAYRY)
- Corteva (CTVA)
- Syngenta (SNYNY)
- Novozymes (NVZMY)
Competitive Landscape
Evogene faces intense competition from larger, more established companies. Its advantage lies in its computational biology platform and innovative approach to product development.
Major Acquisitions
AgPlenus Ltd
- Year: 2020
- Acquisition Price (USD millions): 14.5
- Strategic Rationale: Expanded Evogene's portfolio of novel herbicides and crop protection solutions.
Growth Trajectory and Initiatives
Historical Growth: Evogene's historical growth has been driven by its R&D pipeline and strategic collaborations.
Future Projections: Future growth is dependent on the successful commercialization of its product pipeline and expansion into new markets.
Recent Initiatives: Recent initiatives include partnerships with leading agricultural companies and expansion into the microbiome therapeutics field.
Summary
Evogene is a relatively small biotechnology company with innovative technology and a diverse product pipeline. It faces significant competition and relies heavily on R&D success and strategic partnerships. Expanding the number of successful products that generate revenue would be helpful for the company to improve its financial performance and strengthen its market position. The computational biology platform offers a unique advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Evogene's website
- SEC filings
- Third-party market research reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary. Investing in Evogene involves risks, including the risk of losing money.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evogene
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2008-03-05 | CEO, President & Director Mr. Ofer Haviv CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 117 | Website https://www.evogene.com |
Full time employees 117 | Website https://www.evogene.com | ||
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment focuses on the development and commercialization of improved castor bean seeds for industrial uses. The company also provides medical cannabis products. Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.